Evaluation of anthithrombin III therapeutic effect by frequency of administration in sepsis-associated disseminated intravascular coagulation

Evaluation of anthithrombin III therapeutic effect by frequency of administration in sepsis-associated disseminated intravascular coagulation - Evaluation of anthithrombin III therapeutic effect in sepsis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018074

Enrollment

100

Registered

2015-06-24

Start date

2015-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated disseminated intravascular coagulation

Interventions

1500U of AT was administered to the patients once a day 500U of AT was administered to the patients three times a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient of sepsis-associated disseminated intravascular coagulation which was indicated under 70% of AT III activity.

Exclusion criteria

Exclusion criteria: Age: under 20 years old Hematopoietic malignancy such as lykemia Patient under the anticoagulan treatment such as heparin or warfarin Liver cirrhosis (Child-Pugh score C) The patient will die within a few days regardless of treatment.

Design outcomes

Primary

Measure	Time frame
The period of improving DIC.	—

Secondary

Measure	Time frame
Improvment of coagurative and inflammatory marker	—

Countries

Japan

Contacts

Public ContactRyu Yasuda

Gifu University Hospital Advanced Critical Care Center

yasuryu@gifu-u.ac.jp058-230-6448

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026